NDASUBCUTANEOUSSOLUTION
Approved
Apr 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
KYBELLA (deoxycholic acid) by AbbVie is drug, which when injected into tissue physically destroys the cell membrane causing lysis. First approved in 2015.
Drug data last refreshed 16h ago · AI intelligence enriched 22h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYBELLA is a subcutaneous cytolytic agent containing deoxycholic acid, approved in 2015 for submental fat reduction. It works by directly destroying cell membranes through injection, causing lysis of adipocytes in the chin area. The drug represents a novel, non-surgical approach to a cosmetic concern affecting millions of adults.
Peak5.4 years to LOE
Product is at peak lifecycle stage with established market presence and minimal competitive pressure, suggesting stable but not rapidly expanding commercial teams.
Mechanism of Action
drug, which when injected into tissue physically destroys the cell membrane causing lysis.
Pharmacologic Class:
Cytolytic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis
Started Apr 2026
88 enrolled
Hepatitis AHepatitis E Virus Infection
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products
Started Jan 2025
130 enrolled
Facial Contouring
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Started Jul 2024
92 enrolled
Primary Biliary Cholangitis
A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)
Started May 2024
0Cerebrotendinous Xanthomatoses
Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis
Started Oct 2021
100 enrolled
PBC
Worked on KYBELLA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.